Abstract
Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1718-1731 |
| Number of pages | 14 |
| Journal | Journal of Thoracic Oncology |
| Volume | 14 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2019 |
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials : Consensus Statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. / Gill, Ritu R.; Tsao, Anne S.; Kindler, Hedy L.; Richards, William G.; Armato, Samuel G.; Francis, Roslyn J.; Gomez, Daniel R.; Dahlberg, Suzanne; Rimner, Andreas; Simone, Charles B.; de Perrot, Marc; Blumenthal, Gideon; Adjei, Alex A.; Bueno, Raphael; Harpole, David H.; Hesdorffer, Mary; Hirsch, Fred R.; Pass, Harvey I.; Yorke, Ellen; Rosenzweig, Kenneth; Burt, Bryan; Fennell, Dean A.; Lindwasser, Wolf; Malik, Shakun; Peikert, Tobias; Mansfield, Aaron S.; Salgia, Ravi; Yang, Haining; Rusch, Valerie W.; Nowak, Anna K.
In: Journal of Thoracic Oncology, Vol. 14, No. 10, 10.2019, p. 1718-1731.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials
T2 - Consensus Statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting
AU - Gill, Ritu R.
AU - Tsao, Anne S.
AU - Kindler, Hedy L.
AU - Richards, William G.
AU - Armato, Samuel G.
AU - Francis, Roslyn J.
AU - Gomez, Daniel R.
AU - Dahlberg, Suzanne
AU - Rimner, Andreas
AU - Simone, Charles B.
AU - de Perrot, Marc
AU - Blumenthal, Gideon
AU - Adjei, Alex A.
AU - Bueno, Raphael
AU - Harpole, David H.
AU - Hesdorffer, Mary
AU - Hirsch, Fred R.
AU - Pass, Harvey I.
AU - Yorke, Ellen
AU - Rosenzweig, Kenneth
AU - Burt, Bryan
AU - Fennell, Dean A.
AU - Lindwasser, Wolf
AU - Malik, Shakun
AU - Peikert, Tobias
AU - Mansfield, Aaron S.
AU - Salgia, Ravi
AU - Yang, Haining
AU - Rusch, Valerie W.
AU - Nowak, Anna K.
N1 - Funding Information: Disclosure: Dr. Tsao has received grants from Bristol-Myers Squibb, Lilly, Millenium/Takeda, Seattle Genetics, Ariad, Polaris, Epizyme, Merck, and AstraZeneca; and has received personal fees from Bristol-Myers Squibb, Genentech/Roche, Ariad, Boehringer Ingelheim, AstraZeneca, and Huron. Dr. Kindler has received personal fees from Inventiva, Aduro Biotech, Aldeyra Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Erytech, Five Prime Therapeutics, Ipsen Pharmaceuticals, Kyowa, LSB Biopharma, MedImmune, Merck, Paredox; and has received support from Aduro, Deciphera, GSK, Lilly, Merck, and Verastem. Dr. Armato has received personal fees from Aduro Biotech, Inc.; and receives royalties and licensing fees from The University of Chicago related to computer-aided diagnosis technology. Dr. Gomez has received grants from Merck, Varian, Bristol-Myers Squibb, Reflexion, US Oncology, Onc Live, and AstraZeneca; and has received personal fees from Merck, Varian, Bristol-Myers Squibb, and AstraZeneca. Dr. Dahlberg has served on the steering committee for AstraZeneca; and has a patent: Modeling tumor growth in EGFR+ NSCLC issued to Dana Farber Cancer Institute. Dr. Rimmer has received grants from Varian Medical Systems, Boehringer Ingelheim, Pfizer, and AstraZeneca; and has received personal fees from AstraZeneca, Merck, Research to Practice, Cybrexa, and MoreHealth. Dr. de Perrot has received personal fees from Bayer, Actelion, and Merck. Dr. Bueno has received grants from Roche/Genentech, Verastem, Merck Oncology, Siemens, Epizyme, and Gritstone. Dr. Fennell has received grants from Astex Therapeutics, Boehringer Ingelheim, MSD, and Bayer; and has received personal fees from Aldeyra, Inventiva, Paredox, and Roche; and other support from Clovis, Eli Lilly, and Bristol-Myers Squibb. Dr. Peikert has received support from Novocure and AstraZeneca. Dr. Mansfield has received grants from Verily and Novartis; and has received other support from AbbVie and Genentech. Dr. Rusch has received support from NIH Thoracic Malignancy Steering Committee, Bristol-Myers Squibb, Genelux, Inc., Genentech, and Intuitive Surgical. Dr. Nowak has received grants from AstraZeneca and Douglas Pharmaceuticals; and has received support from Bayer Pharmaceuticals, Roche Pharmaceuticals, Merck Sharp & Dohme, and Boehringer Ingelheim. The remaining authors declare no conflict of interest. Funding Information: Disclosure: Dr. Tsao has received grants from Bristol-Myers Squibb, Lilly, Millenium/Takeda, Seattle Genetics, Ariad, Polaris, Epizyme, Merck, and AstraZeneca; and has received personal fees from Bristol-Myers Squibb, Genentech/Roche, Ariad, Boehringer Ingelheim, AstraZeneca, and Huron. Dr. Kindler has received personal fees from Inventiva, Aduro Biotech, Aldeyra Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Erytech, Five Prime Therapeutics, Ipsen Pharmaceuticals, Kyowa, LSB Biopharma, MedImmune, Merck, Paredox; and has received support from Aduro, Deciphera, GSK, Lilly, Merck, and Verastem. Dr. Armato has received personal fees from Aduro Biotech, Inc.; and receives royalties and licensing fees from The University of Chicago related to computer-aided diagnosis technology. Dr. Gomez has received grants from Merck, Varian, Bristol-Myers Squibb, Reflexion, US Oncology, Onc Live, and AstraZeneca; and has received personal fees from Merck, Varian, Bristol-Myers Squibb, and AstraZeneca. Dr. Dahlberg has served on the steering committee for AstraZeneca; and has a patent: Modeling tumor growth in EGFR+ NSCLC issued to Dana Farber Cancer Institute. Dr. Rimmer has received grants from Varian Medical Systems, Boehringer Ingelheim, Pfizer, and AstraZeneca; and has received personal fees from AstraZeneca, Merck, Research to Practice, Cybrexa, and MoreHealth. Dr. de Perrot has received personal fees from Bayer, Actelion, and Merck. Dr. Bueno has received grants from Roche/Genentech, Verastem, Merck Oncology, Siemens, Epizyme, and Gritstone. Dr. Fennell has received grants from Astex Therapeutics, Boehringer Ingelheim, MSD, and Bayer; and has received personal fees from Aldeyra, Inventiva, Paredox, and Roche; and other support from Clovis, Eli Lilly, and Bristol-Myers Squibb. Dr. Peikert has received support from Novocure and AstraZeneca. Dr. Mansfield has received grants from Verily and Novartis; and has received other support from AbbVie and Genentech. Dr. Rusch has received support from NIH Thoracic Malignancy Steering Committee, Bristol-Myers Squibb, Genelux, Inc., Genentech, and Intuitive Surgical. Dr. Nowak has received grants from AstraZeneca and Douglas Pharmaceuticals; and has received support from Bayer Pharmaceuticals, Roche Pharmaceuticals, Merck Sharp & Dohme, and Boehringer Ingelheim. The remaining authors declare no conflict of interest. Publisher Copyright: © 2019 International Association for the Study of Lung Cancer
PY - 2019/10
Y1 - 2019/10
N2 - Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials.
AB - Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=85072559424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072559424&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2019.08.012
DO - 10.1016/j.jtho.2019.08.012
M3 - Article
C2 - 31470129
AN - SCOPUS:85072559424
VL - 14
SP - 1718
EP - 1731
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 10
ER -